Strategy
Portfolio
People
Careers
April 5, 2021
Having shipped its first benchtop gene editing devices, Inscripta draws another $150M from deep investor well
Back
Portfolio News
Next
Back
Blog
Next
News
Blog
Foresite Labs
Contact Us
Home
Strategy
Portfolio
People
Careers
News
Blog
Foresite Labs
Contact
Investor Login
Terms
Privacy Policy
©2022 Foresite Capital Management, LLC
Site by Goodlab